Salivary Biomarkers for Non-Invasive Screening of Obesity-Related Health Conditions.

Salivary Biomarkers for Non-Invasive Screening of Obesity-Related Health Conditions. - Saliva as an easy method to detect diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON57459

Enrollment

136

Registered

2025-05-06

Start date

2025-04-03

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Participants must be male or female, aged between 18 and 65 years at the time of study participation. 2. For the obese group, participants must have a body mass index (BMI) of >= 30.0 kg/m², while participants in the non-obese group must have a BMI within the range of 18.5-24.9 kg/m². 3. Waist circumference (WC) must meet the following requirements: a. For the obese group: WC of >= 102 cm for men or >= 88 cm for women. b. For the non-obese group: WC of

Exclusion criteria

Exclusion criteria: 1. Self-report or a doctor diagnosis of chronic diseases: cancer/ asthma/ COPD/ Gingivitis/ periodontitis/ Parkinson/ Type 1 diabetes/ kidney disease. 2. Chronic alcoholics 3. Currently an active smoker or residing in a household with smokers. 4. Pregnancy 5. Transgender 6. Sarcopenic obese, as defined in the study protocol. 7. History of bariatric surgery within the past 12 months. 8. Use of medications with anticholinergic effects, including antihistamines, antipsychotics, or antidepressants.

Design outcomes

Primary

Measure	Time frame
The primary endpoints of this study are the diagnostic value of salivary biomarkers, expressed as sensitivity and specificity and summarized by the area under the receiver operating characteristic curve (AUROC), to evaluate their ability in identifying metabolic dysregulations associated with obesity.	—

Secondary

Measure	Time frame
Secondary endpoints include investigating the association between clinical characteristics (e.g., obesity severity, comorbidities, medication use), demographic factors (e.g., age, gender, ethnicity) on the levels, sensitivity, and specificity of salivary biomarkers. Additionally, proteomic technologies using Olink will be used to further uncover the salivary proteomic profile of obese individuals. This approach aims to identify novel biomarkers beyond those highlighted in existing literature, offering new insights into the pathology of obesity for future studies.	—

Measure

Time frame

Secondary endpoints include investigating the association between clinical characteristics (e.g., obesity severity, comorbidities, medication use), demographic factors (e.g., age, gender, ethnicity) on the levels, sensitivity, and specificity of salivary biomarkers. Additionally, proteomic technologies using Olink will be used to further uncover the salivary proteomic profile of obese individuals. This approach aims to identify novel biomarkers beyond those highlighted in existing literature, offering new insights into the pathology of obesity for future studies.

—

Countries

Netherlands

Outcome results